118 related articles for article (PubMed ID: 2897148)
1. Recovery characteristics following antagonism of vecuronium with edrophonium, neostigmine or pyridostigmine.
Yungbluth J; Henry JD; McAnallen K; Albee DT
AANA J; 1988 Apr; 56(2):127-33. PubMed ID: 2897148
[No Abstract] [Full Text] [Related]
2. Neuromuscular blocking action of suxamethonium after antagonism of vecuronium by edrophonium, pyridostigmine or neostigmine.
Fleming NW; Macres S; Antognini JF; Vengco J
Br J Anaesth; 1996 Oct; 77(4):492-5. PubMed ID: 8942334
[TBL] [Abstract][Full Text] [Related]
3. Antagonism of vecuronium paralysis: comparison between edrophonium and neostigmine.
Dernovoi BS
Acta Anaesthesiol Belg; 1991; 42(1):65-71. PubMed ID: 1676233
[TBL] [Abstract][Full Text] [Related]
4. Twitch depression and train-of-four ratio after antagonism of pancuronium with edrophonium, neostigmine, or pyridostigmine.
Donati F; Ferguson A; Bevan DR
Anesth Analg; 1983 Mar; 62(3):314-6. PubMed ID: 6299135
[TBL] [Abstract][Full Text] [Related]
5. Dose-response curves for edrophonium, neostigmine, and pyridostigmine after pancuronium and d-tubocurarine.
Donati F; McCarroll SM; Antzaka C; McCready D; Bevan DR
Anesthesiology; 1987 Apr; 66(4):471-6. PubMed ID: 3565812
[TBL] [Abstract][Full Text] [Related]
6. Electrical and mechanical responses after neuromuscular blockade with vecuronium, and subsequent antagonism with neostigmine or edrophonium.
Astley BA; Katz RL; Payne JP
Br J Anaesth; 1987 Aug; 59(8):983-8. PubMed ID: 2888476
[TBL] [Abstract][Full Text] [Related]
7. [Myasthenia gravis pseudoparalytica. Clinical picture, pathogenesis, therapy].
Kunze K
Med Klin; 1973 Jun; 68(22):723-30. PubMed ID: 4715780
[No Abstract] [Full Text] [Related]
8. Edrophonium: duration of action and atropine requirement in humans during halothane anesthesia.
Cronnelly R; Morris RB; Miller RD
Anesthesiology; 1982 Oct; 57(4):261-6. PubMed ID: 7125261
[TBL] [Abstract][Full Text] [Related]
9. Spontaneous recovery or evoked reversal of neuromuscular block.
Mirakhur RK
Acta Anaesthesiol Scand Suppl; 1995; 106():62-5. PubMed ID: 8533549
[TBL] [Abstract][Full Text] [Related]
10. Optimum time for neostigmine administration to antagonize vecuronium-induced neuromuscular blockade.
Kirkegaard-Nielsen H; Toft P; Severinsen IK; May O
Eur J Anaesthesiol; 1995 Nov; 12(6):585-9. PubMed ID: 8665881
[TBL] [Abstract][Full Text] [Related]
11. The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis.
Tripathi M; Kaushik S; Dubey P
J Postgrad Med; 2003; 49(4):311-4; discussion 314-5. PubMed ID: 14699228
[TBL] [Abstract][Full Text] [Related]
12. Antagonism of pancuronium- and pipecuronium-induced neuromuscular block.
Gyermek L; Cantley EM; Lee C
Br J Anaesth; 1995 Apr; 74(4):410-4. PubMed ID: 7734260
[TBL] [Abstract][Full Text] [Related]
13. Clinical studies on the reversal of the neuromuscular blockade produced by pancuronium bromide. I. The effects of glycopyrrolate and pyridostigmine.
Gyermek L
Curr Ther Res Clin Exp; 1975 Sep; 18(3):377-86. PubMed ID: 810297
[No Abstract] [Full Text] [Related]
14. Antagonism of vecuronium-induced neuromuscular blockade with edrophonium or neostigmine.
Mirakhur RK; Gibson FM; Lavery GG
Br J Anaesth; 1987 Apr; 59(4):473-7. PubMed ID: 2882768
[TBL] [Abstract][Full Text] [Related]
15. Edrophonium is better than neostigmine to antagonize residual vecuronium induced neuromuscular block.
Puura AI; Baer GA; Rorarius MG
Acta Anaesthesiol Belg; 1994; 45(4):161-6. PubMed ID: 7887118
[TBL] [Abstract][Full Text] [Related]
16. The effect of reversal of myoneural blockade on cerebrospinal fluid pressure following cerebral aneurysm surgery.
Fawcett WJ; Chung RA; Fairley CJ; Hollway TE
Eur J Anaesthesiol; 1995 Nov; 12(6):591-5. PubMed ID: 8665882
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic enhancement of neuromuscular transmission in myasthenia gravis.
Riggs JE
Clin Neuropharmacol; 1982; 5(3):277-92. PubMed ID: 6288236
[No Abstract] [Full Text] [Related]
18. Vecuronium block in the myasthenic patient. Influence of anticholinesterase therapy.
Baraka A; Taha S; Yazbeck V; Rizkallah P
Anaesthesia; 1993 Jul; 48(7):588-90. PubMed ID: 8102223
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of new neuromuscular concepts and agents: so long, neostigmine! So long, sux!
Lee C; Katz RL
J Crit Care; 2009 Mar; 24(1):43-9. PubMed ID: 19272538
[TBL] [Abstract][Full Text] [Related]
20. The interaction of human cholinesterases with anticholinesterases used in the therapy of myasthenia gravis.
Foldes FF; Smith JC
Ann N Y Acad Sci; 1966 Jan; 135(1):287-301. PubMed ID: 5221345
[No Abstract] [Full Text] [Related]
[Next] [New Search]
